Cell line · CVCL_0005
Papers62
1 to 20 of 62
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Extracellular vesicle-delivered siRNA targeting RCN1 suppresses acute myeloid leukemia through TFAM-dependent mtDNA-cGAS-STING signaling. | Extracell Vesicles Circ Nucl Acids | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Greatwall kinase regulates acute myeloid leukaemia cell division through a non-canonical mechanism. | EMBO Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Novel noscapine derivative induces AML differentiation by dual-engaging DHODH and mitochondrial lipids to trigger a metabolic-epigenetic-transcriptional cascade. | Acta Pharm Sin B | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A structure-based modeling approach identifies effective drug combinations for RAS-mutant acute myeloid leukemia. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Intracellular iron homeostasis-regulated epigenetic reprogramming contributes to -7/del(7q) leukemia. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Integrative multi-omics, machine learning, and experimental validation reveal that TPM1 suppresses M2 macrophage polarization and enhances chemosensitivity in acute myeloid leukemia. | Cell Biol Toxicol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sialic acid cis-ligand dynamics modulate Siglec-7 and -9 function and affect Siglec-7/9 co-blockade to potentiate natural killer cell anti-tumor activity. | Oncoimmunology | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RBM15B recognizes H3K79me2 to guide selective m6A-modification of mRNA and enhance oncoprotein translation in MLL-r leukemia. | EMBO J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ΔNp73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein. | BMC Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A novel strategy to target metabolic dependencies in acute myeloid leukemia. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Systematic Evaluation of GAPs and GEFs Identifies a Targetable Dependency for Hematopoietic Malignancies. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 40766615 | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms. | Cancer Immunol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models. | Cell Rep Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| BKT300: A Novel Anti-Leukemic Small Molecule Targeting the Protein Regulator of Cytokinesis 1 (PRC1) Pathway | Res Sq | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Thioredoxin-interacting protein (TXNIP) is a substrate of the NEDD4-like E3 ubiquitin-protein ligase WWP1 in cellular redox state regulation of acute myeloid leukemia cells. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the Sodium-Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia. | Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0005/papers